SELENBP1

Across TCGA pan-cancer cohorts, SELENBP1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SELENBP1 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SELENBP1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SELENBP1 expression acts as an unfavorable survival marker.

ACC, HNSC, and MESO are the cancer types where SELENBP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
HNSC	OS	Median	All	0.196	0.768	.001	33	view →
MESO	OS	Median	All	0.130	0.557	.019	18	view →
COAD	OS	Median	All	0.001	0.871	<.001	15	view →
KICH	DFS	Median	All	0.264	0.860	<.001	7	view →
BLCA	OS	Median	All	0.227	0.618	.035	6	view →
LIHC	OS	Median	II,III,IV	0.028	0.772	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SELENBP1–ACC (DFS)

Open the ACC breakdown →